AIT effectiveness on asthma progression
Progression of asthma was analysed
for asthmatic patients at
baseline. With 17.8%, significantly more patients treated with
MCT®-associated allergoids did not receive
prescriptions for symptomatic asthma medication in the follow up period
vs. control group (OR: 0.48; p = 0.004). Significant differences were
also shown for the treatment group of allergoid 2 (16.2%, OR: 0,47;
p < 0.001) and allergoid 3 (14.3%, OR: 0.48;
p < 0.001) and
therefore for the entire AIT treatment group (15.6%, OR: 0.48;
p < 0.001, see Figure 3a).
In addition, the prescriptions of symptomatic asthma medication in the
MCT®-associated allergoid treatment group were
significantly reduced by 35.6%
in the follow-up vs. baseline and control group (p < 0.001).
These effects could also be demonstrated for the allergoid 2, allergoid
3 and entire AIT treatment group (28.3%, 30.1%, 29.1%,
p < 0.001, see Table 2).